Physician profile
Michael La
NPI 1528615101
$863.10
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $66.06 · 2023: $541 · 2024: $98.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $270.42 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.72 | 2022-2023 | Jardiance |
| Pfizer INC. | $116.35 | 2021-2023 | |
| Lilly USA, LLC | $54.13 | 2021-2023 | Trulicity, Mounjaro |
| Alexion Pharmaceuticals, INC. | $54.08 | 2023-2024 | Strensiq |
| Amarin Pharma, INC. | $31.67 | 2021 | |
| Horizon Therapeutics Plc | $25.28 | 2023 | Krystexxa |
| Medtronic, INC. | $25.11 | 2023 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $23.30 | 2022 | |
| Hologic Sales and Service, LLC | $20.95 | 2023 | Aptima, Thinprep 2000 Processor |
| Amgen INC. | $20.16 | 2021 | |
| Organon LLC | $18.23 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.96 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $16.49 | 2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $14.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael La listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.